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ABSTRACT
Objective To calculate the global warming potential, in
carbon dioxide (CO2) equivalent emissions, from a
sample of pragmatic randomised controlled trials.
Design Retrospective analysis.
Data source Internal data held by NIHR Evaluation, Trials
and Studies Coordinating Centre.
Studies included All eligible pragmatic randomised
controlled trials funded by the NIHR Health Technology
Assessment programme during 2002 and 2003.
Main outcomemeasure CO2 equivalents for trial activities
calculated with standard conversion factors.
Results 12 pragmatic randomised controlled trials
involvingmore than4800participants and awide rangeof
technologies were included. The average CO2 emission
generated by the trials was 78.4 (range 42.1-112.7)
tonnes. This is equivalent to that produced in one year by
approximately nine people in the United Kingdom.
Commuting to work by the trial team generated the most
emissions (average 21 (11.5-35.0) tonnes per trial),
followed by study centres’ fuel use (18 (9.3-32.2) tonnes
per trial), trial team related travel (15 (2.0-29.0) tonnes
per trial), and participant related travel (13 (0-46.7)
tonnes per trial).
Conclusions CO2 emissions from pragmatic randomised
controlled trials are generated in areas where steps could
be taken to reduce them. A large proportion of the CO2
emissions come from travel related to various aspects of a
trial. The results of this research are likely to
underestimate the total CO2 emissions associated with
the trials studied, because of the sources of information
available. Further research is needed to explore the
additional CO2 emissions generated by clinical trials, over
and above those generated by routine care. The results
from this project will feed into NIHR guidelines that will
advise researchers on how to reduce CO2 emissions.
INTRODUCTION
Global warming is heavily influenced by human activ-
ity, is considered to be the biggest global health threat
of the 21st century, and is already having impacts on
health.1 2 The Climate Change Act,3 which outlines the
government’s commitment to reduce theUnitedKing-
dom’s carbon output by 80% by 2050, became law in
2008. The National Health Service is committed to
reducing its carbon output,4 5 to which clinical research
contributes. This is manifest in the NHS carbon reduc-
tion strategy, which sets the NHS a target of reducing
its 2007 carbon footprint by 15% by 2015.5
Total public funding for clinical research will be
increased to £1.7 billion (€1.9bn; $2.8bn) by 2010.6
With more funding than ever before available for clin-
ical research, considering its environmental impacts is
increasingly important. As far as we are aware, only
one previous studyhas attempted to quantify the envir-
onmental impact of a clinical trial. That study calcu-
lated the carbon dioxide (CO2) equivalent emissions
of the CRASH trial.7 Total CO2 emissions for the
CRASH trial were estimated at 629 tonnes, or 63 kg
per participant. As the CRASH trial was international
and recruited more than 10 000 participants, it is unli-
kely to be representative of pragmatic randomised
controlled trials in the UK.
As a leading funder of research in the NHS, the
Health Technology Assessment programme of the
National Institute forHealth Research (NIHR) is inter-
ested in the CO2 emissions from the research it funds.
On behalf of the Health Technology Assessment pro-
gramme, the NIHR Evaluation, Trials and Studies
Coordinating Centre (NETSCC) completed a feasibil-
ity study to quantify the CO2 emissions of a rando-
mised controlled trial in the Health Technology
Assessment programme. The analysis was then
extended to a sample of trials to determine which ele-
ments of the trials produce the most emissions. This
paper presents the results of that research.
METHODS
All randomised controlled trials that were funded by
the Health Technology Assessment programme dur-
ing 2002 and 2003 were eligible for inclusion in the
study. We stipulated that the final report of the project
must have been submitted by September 2008 to
ensure that the trials were complete before data collec-
tion began.
We used information that is routinely held by
NETSCC. The main sources of data were the project
files and the published monograph, or the final report
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of the project if it had yet to be published. Project files
are used for monitoring purposes and contain docu-
ments such as grant application forms, six monthly
progress reports, extension requests, and minutes of
steering group meetings.
Using the methods of the CRASH audit,7 the NHS
footprinting report,5 and the greenhouse gas reporting
protocol developed by the World Business Council,8
we compiled a list of elements of trials that we believed
would generate CO2 emissions and a list of the activ-
ities within each element that would generate the emis-
sions.We searched the data sources for information on
these activities and any other activities not included in
the list that we believed had a CO2 value. The box
shows the elements and activities of trials for which
we collected data.
We used standard conversion factors to convert the
data intoCO2values.The information contained in the
data sources was not always sufficient to allow us to do
the calculations. In these instances, we made informed
assumptions to supplement the information and allow
it to be converted into CO2. The conversion factors
and assumptions used are detailed below.
Transport
National travel—We used a conversion factor of 0.25 to
calculate the CO2 emissions per kilometre travelled.
This conversion factor comes from the NHS footprint-
ing report and accounts for thedirect and indirect emis-
sions from all modes of transport.5 We used Google
maps UK to calculate all distances. We assumed that
staff travelled to meetings from their workplace. In the
absence of detailed information about travel, we calcu-
lated CO2 from the amount of money spent on
journeys. We used a conversion factor of 0.43 kg of
CO2 per pound spent, which we derived from the
NHS footprinting report.5
International travel—We calculated the CO2 value of
any flights that were made during the trial by using a
CO2 calculator available at the climate care website
(www.climatecare.org/roughguides/). The tool calcu-
lates the CO2 emissions from a return flight between
any two cities. We assumed that travellers departed
from the nearest airport to their place of work and
flew directly to the airport of the city to which they
were travelling.
Distances
Primary care—We assumed the distance travelled for
primary care visits to be 2.4 km. This is the average
distance that patients live from their general practice,
according to data from an Ipsos-MORI survey for the
Department of Health (DH, personal communication,
2008).
Secondary care—Weassumed the distance travelled to
secondary care visits to be17.4 km.We took this froma
study using hospital episode statistics data, which
found that 17.4 km was the median distance that
patients travel for elective hospital visits.9
Staff commuting—We assumed the distance travelled
by staff commuting to work on the trial to be 14 km,
which was found to be the average distance commuted
to work in the national travel survey 2006.10 We
assumed that trial employees would take 40 days’
leave pro rata, including 30 days’ annual leave and
10 days’ sick leave.11
Energy consumption at study centres
Wecalculated energy consumption at the study centres
by using conversion factors available from the Depart-
ment for Food Environment and Rural Affairs.12 The
amount of energy used differs according to the type of
accommodation. Table 1 shows the conversion factors
we used for different types of accommodation, which
represent the amount of energy used per square metre
of office space in a year. We assumed that each
employee would be allocated 10 m2 of office space,
which was recommended by the Carbon Trust (Car-
bon Trust, personal communication, 2008).
Manufacture and delivery of trial technologies
We calculated the energy used in the manufacture and
delivery of the trial technologies from the amount of
funding allocated for the purchase of the technologies.
This method was used in the NHS report.5 We
Trial elements and activities for which data were collected
Study centres
 Fuel use
Participant related travel
 Participants’ travel
 Visitors’ travel
Trial team commuting
 Staff commuting to work
Trial team related travel
 Travel for steering group meetings
 Travel for data monitoring committee meetings
 Trial coordinator’s travel
 Travel for training
 Travel to conferences
 Travel for Health Technology Assessment monitoring visits
 Other trial meetings/travel
Information technology equipment
 Energy use in manufacture
Trial technologies
 Energy use in manufacture
 Distribution and deliveries
Table 1 | Conversion factors for energy use at study centres
Type of accommodation Total CO
2
(kg/m2/year)
Hospital: teaching and specialist 17.49
General practice/health centre/outpatients 65.79
Primary school 47.52
Acute and maternity 18.64
Office: air conditioned 154.30
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assumed that 95% of the money allocated to trial tech-
nologies in the full proposal was used to purchase the
technology and that the remaining 5% was spent on
delivering the technology. We did not find any evi-
dence on which to base these figures. Table 2 shows
the conversion factors used to calculate the emissions
for different types of technology.
Information technology equipment
We calculated the CO2 emissions relating to the pro-
duction of information technology equipment for the
trials from the amount of money spent on the purchase
of such equipment during the trial. We used a conver-
sion factor of 0.21, which came from the NHS foot-
printing report.5
Sensitivity analysis
In our analysis, we calculated the total CO2 emissions
of the trials, including those that would have occurred
as part of routine practice as well as those solely
attributable to the trial, as we could not separate these
emissions in our data. One could argue that staff
commuting to work should not be included in the ana-
lysis, as the researchers would still need to commute to
work even if they were working in another field. To
account for this, we did a sensitivity analysis to calcu-
late the CO2 emissions of the trials excluding those
generated by staff’s commuting.
RESULTS
Twelve randomised controlled trials met the inclusion
criteria (fig 1), involving more than 4800 participants
and a wide range of technologies, including medical
devices, pharmaceuticals, and psychological therapies.
The average number of participants was 402, the aver-
age cost per participant was approximately £2500, and
the average number of study centres was 16.
We calculated the total CO2 emissions generated by
the 12 trials as 941.2 tonnes, which is equivalent to that
produced in one year by about 103 people in theUK.13
Table 3 shows the CO2 emissions for each trial, which
ranged from 42.1 tonnes to 112.7 tonnes.
Our analysis shows that the average amount of CO2
produced by the trials was 78.4 tonnes, equivalent to
that produced in one year by about nine people in the
UK.13 The average amount of CO2 produced in one
year of a trial was 18.1 (range 8.9-30.1) tonnes. On
average, the trials produced 306.2 (80.0-883.7) kg of
CO2 per participant, 0.1 (0.07-0.15) kg of CO2 per
pound spent, and 5.6 (3.8-9.5) tonnes of CO2 per
whole time staff member.
Across all of the trials, commuting to work by trial
teams accounted for the most CO2 emissions (26%),
followed by use of fuel at study centres (23%) and
trial team related travel (19%). Participants’ travel
accounted for 16% of emissions, trial technologies
accounted for 14% of emissions, and information tech-
nology equipment accounted for 2% of emissions. The
amount of CO2 that was generated from different trial
elements varied between the randomised controlled
trials (fig 2).
The CO2 emissions generated by participant related
travel ranged from 0 to 46.7 tonnes (average 12.6
tonnes per trial). This variation can in part be
explained by the difference in the number of visits
that were required in the different trials, which ranged
from none to 36. Additionally, participants’ visits took
place in a variety of locations in secondary care, pri-
mary care, and the community, which corresponds to
the use of different distances in our calculations.
The amount of CO2 produced by trial team related
travel ranged from 2.0 to 29.0 tonnes (average 14.7
tonnes per trial), owing to the different activities in
the trials and the organisation of the trials. For exam-
ple, the number of steering group meetings needed for
the trials ranged from three to 10, and the number of
people attending ranged from four to 13. The number
of site visits the trial coordinatorsmadeduring the trials
also varied greatly. The average number of confer-
ences that the trial teams attended ranged from one to
21 (total 78, of which 16 were international).
The CO2 generated from use of fuel at the study cen-
tres ranged from9.3 to 32.2 tonnes (average 18.1 tonnes
per trial), and that generated from the trial team com-
muting to work ranged from 11.5 to 35.0 tonnes (aver-
age 20.9 tonnes per trial). These calculationswere based
on the number of staff working on the trial, the length of
time they were employed on the trial, and the type of
accommodation they occupied.
The CO2 emissions related to the trial technology
ranged from 0 to 35.9 tonnes (average 10.7 tonnes
per trial), and emissions related to information technol-
ogy equipment ranged from 0.4 to 2.9 tonnes (average
1.5 tonnes per trial). The CO2 emissions from these
elements are directly proportional to the cost of the
technologies.
Table 2 | Conversion factors for manufacture and delivery of
trial technology
Pharmaceuticals 0.24 0.51
Medical instruments/equipment 0.20 0.51
Primary research funded by HTA in 2002/3 (n=27)
RCTs funded by HTA in 2002/3 (n=21)
RCTs that had submitted final report by September 2008 (n=17)
RCTs included (n=12)
RCTs excluded (n=4): 
  Discontinued (n=1)
  Final report not submitted (n=3)
RCTs excluded (n=5): 
  Changed to qualitative study (n=1)
  Data unavailable (n= 1)
  Insufficient information to do calculations (n=2)
  Used in feasibility study (n=1)
Fig 1 | Flow diagram of included and excluded randomised
controlled trial (RCTs). HTA= Health Technology Assessment
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Sensitivity analysis
A sensitivity analysis excluding the emissions gener-
ated by staff commuting towork found that the average
amount of CO2 produced by the trials was 57.6 (27.9-
80.3) tonnes, which is equivalent to that produced in
one year by about six people in the UK.13 On average,
the trials produced 13.3 (5.9-20.7) tonnes of CO2 a
year, 218.0 (53.2-561.9) kg of CO2 per participant,
0.08 (0.06-0.12) kg of CO2 per pound spent, and 4.2
(2.4-8.1) tonnes of CO2 per whole time staff member.
Table 3 shows the individual results of the sensitivity
analysis for each trial.
DISCUSSION
We found thatmost of theCO2 emissions produced by
pragmatic randomised controlled trials come from
trial related travel (including commuting by the trial
team and participant and trial team related travel)
and use of fuel at the study centres. The trials varied
in the proportion of CO2 generated by different ele-
ments of the trial.
Strengths and weaknesses
This is the first studywe are aware of that has attempted
to calculate theCO2 emissions from a sample of rando-
mised controlled trials involving a range of technolo-
gies and groups of participants. The trials took place in
various settings and were based in multiple centres
throughout the UK. Perhaps a more accurate way to
calculate the CO2 emissions of a trial would be to pro-
spectively collect information on activities with a CO2
value for the duration of the trial. Although this might
provide amore accurate estimate, it would be very bur-
densome on time and resources. We therefore believe
that, although our analysis may not represent the exact
CO2 emissions producedby these trials, it does provide
a good guide as to the level of CO2 emitted and the trial
related activities that generate the most emissions.
The study has some limitations. We did the study
retrospectively using data that was not designed for
this purpose, which had several implications. Use of
project files and reports meant that we attributed
CO2 values to the trial related activities reported,
rather than all of the activities executed. Therefore,
the results of this research are likely to be an underes-
timate of the total CO2 emissions associated with the
trials studied. The information we needed to calculate
the CO2 value was not always available, which meant
that data had to be supplemented with assumptions.
The amount of information contained within the files
varied betweenprojects, resulting in a variable number
of assumptions being used for each trial.
We excluded two eligible trials from the study, as the
information available was insufficient to allow us to do
the calculations.We know that these studies involved a
lot of travel, and theymay have had a largerCO2 value
than the other studies that were included.
Comparisons with other studies
The only previous work in this area was a carbon audit
of the CRASH trial,7 which was estimated to have pro-
duced 629 tonnes of CO2. Our estimate of the average
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Fig 2 | CO2 emissions generated by different elements of
randomised controlled trials studied. Each box shows the
median, with 25th and 75th centiles; vertical lines extend to
minimum and maximum values
Table 3 | CO2 emissions for each trial included in study
Trial No
No of
participants
Cost per participant
(to nearest £100)
Total CO
2
(t)
CO
2
per year
(t)
CO
2
per participant
(kg)
CO
2
per £ spent
(kg)
CO
2
per WTE staff
(t)
1 201-300 £1900 42.1 (27.9) 8.9 (5.9) 175.5 (116.2) 0.09 (0.06) 4.1 (2.7)
2 >500 £670 46.7 (31.1) 13.4 (8.9) 80.0 (53.2) 0.12 (0.08) 4.2 (2.8)
3 >500 £1200 52.6 (41.1) 12.6 (9.9) 89.9 (70.3) 0.07 (0.06) 6.4 (5.0)
4 >500 £1200 72.0 (52.1) 19.6 (14.2) 130.6 (94.5) 0.11 (0.08) 5.1 (3.7)
5 301-500 £2400 72.9 (52.1) 13.9 (9.9) 211.9 (151.5) 0.09 (0.06) 4.9 (3.5)
6 0-200 £7300 76.0 (48.3) 14.2 (9.1) 883.7 (561.9) 0.12 (0.08) 3.8 (2.4)
7 201-300 £3700 85.3 (56.1) 19.3 (12.7) 387.7 (255.2) 0.11 (0.07) 4.1 (2.7)
8 201-300 £2800 86.2 (73.4) 19.2 (16.3) 397.3 (338.4) 0.14 (0.12) 9.5 (8.1)
9 301-500 £1400 91.2 (77.1) 20.3 (17.1) 201.3 (170.2) 0.15 (0.12) 9.2 (7.8)
10 >500 £1000 101.5 (73.5) 20.7 (14.9) 95.0 (68.7) 0.09 (0.07) 5.1 (3.7)
11 301-500 £2100 102.0 (80.3) 25.0 (19.7) 321.6 (253.2) 0.15 (0.12) 6.6 (5.2)
12 0-200 £4800 112.7 (77.7) 30.1 (20.7) 700.2 (482.7) 0.15 (0.10) 4.5 (3.1)
Values in parentheses relate to sensitivity analysis excluding CO2 from staff commuting to work.
WTE=whole time equivalent.
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CO2 emission per trial was lower at 78 tonnes. How-
ever, the CRASH trial included 10 000 participants,
whereas the average number of participants per trial
in our sample was 402. The average CO2 emission
per participant in our study was 306 kg, whereas the
corresponding figure in the CRASH trial was 63 kg,
suggesting that per participant the CRASH trial was
much less carbon intensive. The CRASH trial was a
large simple trial of an acute care intervention. It
involved no extra tests, and data collection was mini-
mal and based entirely on the patients’ clinical notes.
Statistical data monitoring reduced the need for multi-
ple site visits, whichwould have involved considerable
amounts of extra travel. The CRASH trial did not
involve any extra travel by participants, whereas
most of the trials in our study involved several visits.
These factors may account for the difference in CO2
emissions per participant between our study and the
CRASH trial. Nevertheless, the proportions of CO2
emissions from different trial elements were similar
between the two studies. Two of the most CO2 inten-
sive elements of the CRASH study were use of fuel at
the coordinating centre and trial related travel, which is
consistent with our findings.
Meaning of study
The government is committed to drastically reducing
CO2 emissions,3 and all sectors must contribute to this
reduction. Clinical research contributes to the NHS’s
carbon footprint, and the research community should
be aware of the CO2 emissions generated by their
trials. This research shows that most CO2 emissions
from randomised controlled trials are generated in
areas in which steps could be taken to reduce them.
When aiming to minimise CO2 emissions, trialists
and funders should focus particular attention on the
emissions generated by participants’ travel and travel
by the trial team, which can be reduced with simple
changes. The number of visits by participants that are
required for a trial should be kept to aminimum.Care-
ful consideration of each visit and its purpose may
show that the trial could be completed with fewer visits
or that several visits could be combined. Alternative
methods that do not require face to face encounters,
such as telephone interviews, may be available for
some assessments of participants. Some of the trials in
our study have shown that simple steps can reduce the
amount of travelling staff do during the trial and there-
fore lower CO2 emissions. For example, some trials
held meetings by teleconference to reduce travel; in
one study, meetings were held in a location that was
withinwalking distance for people attending. Technol-
ogies such as teleconferencing or videoconferencing
could be used more and have the potential to reduce
the carbon output from trials. This research will feed
intoNIHRguidelines that will expand on these recom-
mendations and advise researchers on how to reduce
CO2 emissions from their trials and other research.
Unanswered questions and further research
In our analysis, wewere unable to separate excess CO2
emissions from those that occur during routine care.
Further work is needed to explore the additional CO2
emissions generated by randomised controlled trials
over and above those generated by routine care. Our
analysis included a range of randomised controlled
trials, but we did not explore the effect of different
research designs on CO2 output, so further research
is needed to explore the CO2 emissions from other
study designs. This study has developed methods to
calculate the CO2 emissions associated with trials.
These methods could be expanded on and developed
into a tool for use by researchers and funders to allow
the carbon cost of a trial to be considered at the plan-
ning stage.
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